ODAC meets to determine fate of Marqibo in Ph- ALL

The Oncologic Drugs Advisory Committee (ODAC) is meeting today to vote on whether the benefits outweigh the risks for Marqibo (vincristine sulfate liposomal injection) for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) whose disease has relapsed or who have previously undergone at least two other treatments with anti-leukemia drugs.

ALL more frequently affects children; only about 2,000 cases are diagnosed in adults in the US annually. About 70 percent of them are Philadelphia chromosome negative ALL.

It is an especially difficult disease to treat; in fact few treatments exist for this patient population, which is one of the arguments put forth by Talon pharmaceuticals, makers of Marqibo.

But Talon has an uphill battle, chiefly because the data submitted to the committee comes from a Phase II single-arm, open-label, dose-escalation trial of 65 patients. The FDA has always been clear about its heavy preference for randomized controlled trials and for not thinking much of single-arm trials.

Either way, Marqibo confers added survival of a few months in less than 20 percent of those who receive it. Furthermore, patients with relapsed Ph- ALL have a grim five-year survival rate of 7 percent.

Source: MedPageToday

lymphoma roundup

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...